Selinexor attenuates the growth of cancer cells and induces selinexor-resistant cells to become sensitive to selinexor by stabilizing IκB to inhibit the NF-κB pathway and then downregulating the expression of survivin protein. The gene discussed is NFKB1; the disease is cancer.